According to the repatency indexes of non-traumatic coronary arteries a comparison was made between the repatency rates of coronary arteries of AMI patients treated by urate oxidase and by non-thrombolytic therapy .

采用非创伤性冠脉再通指标，比较AMI发病后≤6小时和6～12小时静脉 应用 尿激酶治疗 31例和非溶栓治疗59例AMI患者的冠脉再通率。

Expression and purification of urate oxidase and identification of its bioactive type

尿酸 氧化酶的表达纯化及活性形式鉴定

Since the urate oxidase in human body does not have activity the current clinical application of urate oxidase is mainly rooted from Aspergillus flavus . Since it is a foreign protein with immunogenicity clinical application is greatly limited .

由于人体内的 尿酸 氧化酶不具有活性，目前临床上用的尿酸氧化酶主要来自黄曲霉菌（aspergillusflavus），因其是外源蛋白，具有免疫原性，临床应用受到极大限制。

Curative effect and administering time of urate oxidase in treating AMI

静脉 应用 尿激酶治疗急性心肌梗塞疗效与给药时间关系的探讨

Studies have shown that urate oxidase can far superior in reducing uric acid levels than other drugs in scale and speed .

有研究表明， 尿酸 氧化酶降低体内尿酸水平的幅度和速度远远优于其它药物。

It has been reported that the urate oxidase with PEG-modified can reduce its immunogenicity but enzyme activity has decreased greatly after PEG modified .

已有研究通过PEG化修饰 尿酸 氧化酶以降低其免疫原性，但经PEG修饰后酶的催化活性下降幅度较大。